RPS6KA3

Overview

RPS6KA3 (RSK2) encodes ribosomal protein S6 kinase A3, a serine/threonine kinase downstream of RAS-MAPK signaling. It is cataloged among somatic alterations in the HCC mutational landscape from large-scale genomic profiling.

Alterations observed in the corpus

• RPS6KA3 is listed in the HCC mutational gene catalog from WES of 1,289 patients; individual mutation frequency not separately enumerated in the review text. PMID:24798001
• Significantly mutated (MutSigCV) in 7% of HCC cases; inactivating mutations shown in vitro to elevate phospho-ERK1/2, indicating RAS/MAPK pathway activation; RPS6KA3-mutated HCC nominated as candidates for MEK/ERK inhibition. PMID:25822088

Cancer types (linked)

• HCC — identified in comprehensive WES-based HCC mutational profiling (n=1,289). PMID:24798001

Co-occurrence and mutual exclusivity

• No co-occurrence or mutual exclusivity data reported in the current corpus.

Therapeutic relevance

• No direct RPS6KA3-targeted therapy data reported in the current corpus.

Open questions

• Individual mutation frequency and clinical significance in HCC require further characterization.

Sources

• PMID:24798001

This page was processed by crosslinker on 2026-05-14. - PMID:25822088

This page was processed by crosslinker on 2026-05-14.